Anixa Biosciences, Inc.

Anixa Biosciences, Inc. is a clinical-stage biotechnology company dedicated to the development of therapies and vaccines for critical unmet needs in oncology. The company's mission centers on leveraging the body's immune system to combat cancer, with its headquarters located in San Jose, California.

Anixa Biosciences' pipeline includes a cancer immunotherapy program featuring a novel chimeric endocrine receptor T-cell (CER-T) technology, known as Lira-cel, which is being developed for ovarian cancer. Additionally, the company maintains a vaccine portfolio focused on immunizing against specific "retired" proteins associated with various cancers. This includes a breast cancer vaccine targeting α-lactalbumin, an ovarian cancer vaccine, and a discovery program for vaccines against lung, colon, and prostate cancers. These programs are advanced through collaborations with institutions such as the Cleveland Clinic and Moffitt Cancer Center.

Recent developments for Anixa Biosciences include strengthening its intellectual property with new patents for its ovarian and breast cancer vaccine technologies. The company has also reported positive survival observations from the ongoing Phase 1 trial of its Lira-cel ovarian cancer CAR-T therapy. Furthermore, its breast cancer vaccine has successfully completed Phase 1 trials, demonstrating positive safety and immune response data, and is progressing towards Phase 2 clinical trials. Dr. Amit Kumar serves as the Chairman and CEO, leading the company's strategic direction in the clinical biotechnology sector.